Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
iXLife Capital is a venture capital firm specializing in biotech investments, founded in 2010 and based in Marly-le-Roi, near Paris, France. The firm is dedicated to identifying and supporting early-stage companies that develop innovative therapies and devices for cancer, neurological conditions, and other diseases. Since its inception, iXLife Capital has concentrated its efforts on building a portfolio of companies that emphasize therapeutic innovation and drug discovery.
As of 2025, iXLife Capital manages a small portfolio of approximately five companies under its iXLife 1 fund. The firm operates primarily in France and Switzerland, focusing on seed and Series A investments. iXLife Capital's commitment to advancing healthcare solutions is evident in its strategic support for portfolio companies, guiding them through the complexities of drug development and market entry.
iXLife Capital has established a presence in both France and Boston, although its primary operations are centered in France. The firm has not publicly disclosed its fund size or limited partner base, but it actively seeks to partner with innovative biotech startups that align with its investment thesis.
iXLife Capital invests in early-stage biotech companies that are developing innovative therapies and technologies, particularly in the fields of oncology, neurology, and rare diseases. The firm primarily targets seed and Series A funding rounds, with check sizes ranging from $1 million to $6 million. Their investment strategy emphasizes therapeutic innovation, drug discovery, and genome editing technologies.
The geographic focus of iXLife Capital is on France and Switzerland, where it seeks to identify companies that are addressing significant health challenges. The firm looks for founders who demonstrate a strong commitment to advancing healthcare solutions and possess a clear vision for their products. iXLife Capital's investment approach includes providing strategic support to portfolio companies, helping them navigate the complexities of the biotech landscape.
iXLife Capital's portfolio consists of five notable biotech companies:
This concentrated portfolio reflects iXLife Capital's commitment to supporting companies that are at the forefront of therapeutic innovation.
Jean-Pierre Kinet — Managing Partner. Jean-Pierre has extensive experience in biotech investment and has led numerous successful funding rounds in the sector. His expertise includes therapeutic innovation and drug discovery, making him a key resource for portfolio companies.
To pitch iXLife Capital, founders should use the contact page available at ixlife.com/contact. It is important to include a comprehensive deck that outlines the business model, technology, and team qualifications. iXLife Capital prefers to receive pitches via this channel and typically responds within a few weeks.
As of May 2025, iXLife Capital has made a new investment in Quidditas, which specializes in genome editing technology, raising €2.62 million. In September 2023, the firm led a €1.2 million seed round for SeaBeLife, focusing on therapies for acute liver disease and eye disorders. The firm has been actively identifying and evaluating biotech companies for investment, maintaining a clear focus on supporting the development of new medicines and medical devices.
What are iXLife Capital's investment criteria?
iXLife Capital focuses on seed and Series A investments in biotech companies that develop innovative therapies for oncology, neurology, and rare diseases. They seek companies that demonstrate a strong commitment to advancing healthcare solutions.
How can I pitch to iXLife Capital?
Founders can pitch to iXLife Capital through their contact page at ixlife.com/contact. It is advisable to include a detailed business plan and information about the team and technology.
What makes iXLife Capital different from other investors?
iXLife Capital specializes in biotech investments and provides strategic support to its portfolio companies, leveraging its expertise in drug development and market entry.
What is the geographic scope of iXLife Capital's investments?
The firm primarily invests in companies located in France and Switzerland, focusing on the biotech sector.
What is the typical check size for investments?
iXLife Capital typically invests between $1 million and $6 million in its portfolio companies.
What kind of post-investment involvement does iXLife Capital have?
iXLife Capital actively supports its portfolio companies through mentorship and guidance in navigating the complexities of drug development and market entry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.